Intel shares surged 14% to touch an all-time high after reports surfaced that Apple is considering Intel chips for U.S. manufacturing. The rally caps a historic run for the chipmaker, which logged a 114% gain last month alone.
The talks with Apple represent a significant strategic shift. Intel has struggled for years against competitors like TSMC and Samsung in advanced chip design. A partnership with Apple, the world's most valuable company, would validate Intel's manufacturing capabilities and provide substantial revenue. Apple currently relies on its own in-house designs and TSMC for production.
The timing reflects Intel's turnaround efforts under CEO Pat Gelsinger. The company received $20 billion in CHIPS Act funding and launched initiatives to become a contract manufacturer for external customers. A deal with Apple would mark a watershed moment, demonstrating that Intel can compete for premium semiconductor work.
Market sentiment has shifted dramatically. Investors have rewarded Intel heavily on expectations for government support and potential new customer wins. The stock's 114% monthly gain positioned it among the best performers in the semiconductor sector. Today's 14% jump reflects renewed confidence in a partnership that could reshape Intel's business model.
For Apple, the move signals diversification away from Taiwan. Geopolitical risks and supply chain vulnerabilities have pushed the company to explore U.S. manufacturing options. Using Intel's domestic fabs would align with reshoring trends and reduce dependence on Asian suppliers.
The deal remains in discussion stage with no confirmation from either company. Success hinges on whether Intel can produce chips meeting Apple's exacting standards at competitive costs. Previous attempts by Intel to win major customers have yielded mixed results.
Still, the market's reaction underscores how transformative such a partnership could be. For Intel, it represents vindication of its costly manufacturing strategy. For investors, it offers proof that the company's recovery narrative holds traction.